Oncology continues to drive M&A and dealmaking activity

1 July 2022

An analysis of how - and why - oncology remains the hottest area for big-money deals in pharma.

As always, last month's American Society of Clinical Oncology (ASCO) meeting captured a lot of attention from companies and investors, with important new data being presented on Sanofi’s (Euronext: SAN) antibody drug conjugate, Sarclisa (isatuximab) in multiple myeloma, Astellas Pharma (TYO: 4503) Phase III EV-301 trial data with enfortumab vedotin in pre-treated patients with advanced or metastatic urothelial cancer, as well as data from newcomers including I-Mab (Nasdaq: IMAB) with its new CD73 antibody uliledlimab in combination with Roche’s (ROG:SIX) Tecentriq in patients with advanced cancer, and Adicet Bio's (Nasdaq: ACET) off the shelf gamma-delta T-cell therapy ADI-001, in lymphoma.

So why is there such continued interest and investment in oncology?

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK